Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →
One Biosciences receives €3.3 million funding to accelerate the development of its single-cell diagnostic for triple-negative breast cancer. The funding is part of the i-Démo 5 program from France 2030.
Sep 11, 2026•about 2 hours ago
ParisBiotechnologyDescription
One Biosciences has secured €3.3 million to support the development of its first single-cell profiling diagnostic for triple-negative breast cancer. This funding is provided under the i-Démo 5 initiative from France 2030. The program aims to enhance treatment decisions for this challenging cancer type. This collaboration with Institut Curie underscores the importance of innovative diagnostics.
Agreement Insights
Based on industry dataContract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months
One Biosciences signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.